While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

A fast-rising form of breast cancer that's harder to detect on mammograms now makes up more than one in ten cases in the United States, according to a new report from the American Cancer Society (ACS) ...

Women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive lobular carcinoma who are treated with endocrine therapy do not derive any additional ...

NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better ...

Scientists are warning that rates of a rare but highly deadly cancer are on the rise in the US, with cases climbing three times faster than other, more common, cancers. A key finding from 2012 to 2021 ...